Alliin
Catalog No: CFN93533
Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase, hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. Alliin has anti-inflammatory activity, it protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response; alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. Alliin and sabinene have detectable levels of antimicrobial activity.